A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer

被引:60
作者
Bahreini, Fatemeh [1 ]
Soltanian, Ali Reza [2 ]
Mehdipour, Parvin [1 ]
机构
[1] Univ Tehran Med Sci, Dept Med Genet, Sch Med, Tehran 1417613151, Iran
[2] Hamadan Univ Med Sci, Dept Biostat & Epidemiol, Modeling Noncommunicable Dis Res Ctr, Sch Publ Hlth, Hamadan 65155, Iran
关键词
HER2; Immunohistochemistry; Fluorescence in situ hybridization; Breast cancer; Meta-analysis; GROWTH-FACTOR RECEPTOR; TISSUE MICROARRAY; COST-EFFECTIVENESS; ESTROGEN-RECEPTOR; IMAGE-ANALYSIS; CORE BIOPSY; HER-2/NEU; EXPRESSION; AMPLIFICATION; ANTIBODIES;
D O I
10.1007/s12282-014-0528-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We performed this meta-analysis study to evaluate the concordance and discordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in detecting HER2 alteration in human breast cancer. Methods As a meta-analysis, the present study evaluated the available data from previous studies on the HER2 gene detected by IHC and FISH. To indicate the meta-analysis results, a forest plot was used. Results We identified 172 citations, for which our inclusion criteria were met by 18 articles, representing 6629 cases. The overall concordance and discordance rate between IHC staining with score 0/1+ and FISH for detection failure of HER2 expression was 96 and 4 %, respectively. The present study showed that the overall proportion of FISH positive and negative rate for IHC score 2+ for detection of HER2 expression was 36 and 64 %, respectively; and 91 and 9 % for 3+ IHC scores. Conclusion The results of this study show that IHC score 0/1+ and 3+ cannot be completely considered as negative and positive breast cancer test, respectively. Therefore, we suggest a valid and complementary test, the same as FISH, to explore HER2 expression.
引用
收藏
页码:615 / 625
页数:11
相关论文
共 97 条
[21]   Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer [J].
Chumsri, Saranya ;
Jeter, Stacie ;
Jacobs, Lisa K. ;
Nassar, Hind ;
Armstrong, Deborah K. ;
Emens, Leisha A. ;
Fetting, John H. ;
Lange, Julie R. ;
Riley, Carol ;
Tsangaris, Theodore N. ;
Wolff, Antonio C. ;
Zellars, Richard ;
Zhang, Zhe ;
Stearns, Vered .
CLINICAL BREAST CANCER, 2010, 10 (01) :40-45
[22]   Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer [J].
Conlin, Alison K. ;
Seidman, Andrew D. ;
Bach, Ariadne ;
Lake, Diana ;
Dickler, Maura ;
D'Andrea, Gabriella ;
Traina, Tiffany ;
Danso, Michael ;
Brufsky, Adam M. ;
Saleh, Mansoor ;
Clawson, Alicia ;
Hudis, Clifford A. .
CLINICAL BREAST CANCER, 2010, 10 (04) :281-287
[23]  
Dank M, 2001, Orv Hetil, V142, P2563
[24]   Secretory carcinoma of the breast:: A distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry [J].
Diallo, R ;
Schaefer, KL ;
Bankfalvi, A ;
Decker, T ;
Ruhnke, M ;
Wülfing, P ;
Jackisch, C ;
Luttges, J ;
Sorensen, PHB ;
Singh, M ;
Poremba, C .
HUMAN PATHOLOGY, 2003, 34 (12) :1299-1305
[25]   Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres [J].
Dowsett, M ;
Bartlett, J ;
Ellis, IO ;
Salter, J ;
Hills, M ;
Mallon, E ;
Watters, AD ;
Cooke, T ;
Paish, C ;
Wencyk, PM ;
Pinder, SE .
JOURNAL OF PATHOLOGY, 2003, 199 (04) :418-423
[26]   Assessment of HER2 status in breast cancer: why, when and how? [J].
Dowsett, M ;
Cooke, T ;
Ellis, I ;
Gullick, WJ ;
Gusterson, B ;
Mallon, E ;
Walker, R .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (02) :170-176
[27]   Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial [J].
Dowsett, Mitch ;
Procter, Marion ;
McCaskill-Stevens, Worta ;
de Azambuja, Evandro ;
Dafni, Urania ;
Rueschoff, Josef ;
Jordan, Bruce ;
Dolci, Stella ;
Abramovitz, Mark ;
Stoss, Oliver ;
Viale, Giuseppe ;
Gelber, Richard D. ;
Piccart-Gebhart, Martine ;
Leyland-Jones, Brian .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :2962-2969
[28]   Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma [J].
Drev, Primoz ;
Grazio, Snjezana Frkovic ;
Bracko, Matej .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2008, 16 (02) :179-184
[29]   Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab [J].
Dybdal, N ;
Leiberman, G ;
Anderson, S ;
McCune, B ;
Bajamonde, A ;
Cohen, RL ;
Mass, RD ;
Sanders, C ;
Press, MF .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) :3-11
[30]   Re: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: Comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility [J].
Egervari, Kristof ;
Szollosi, Zoltan ;
Nemes, Zoltan .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2008, 16 (05) :510-511